CCL2 and depressive disorder: The intervention significantly reduced proinflammatory mediators (TNF-α, IL-17, IL-23, MCP-1, IFN-γ, and IL-12) and improved depression, anxiety, resilience and well-being with sustained effect over a three-week follow-up.